Your browser doesn't support javascript.
loading
Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study.
Allen, Isaac; Hassan, Hend; Joko-Fru, Walburga Yvonne; Huntley, Catherine; Loong, Lucy; Rahman, Tameera; Torr, Bethany; Bacon, Andrew; Knott, Craig; Jose, Sophie; Vernon, Sally; Lüchtenborg, Margreet; Pethick, Joanna; Lavelle, Katrina; McRonald, Fiona; Eccles, Diana; Morris, Eva J A; Hardy, Steven; Turnbull, Clare; Tischkowitz, Marc; Pharoah, Paul; Antoniou, Antonis C.
Afiliação
  • Allen I; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Hassan H; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Joko-Fru WY; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Huntley C; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Loong L; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Rahman T; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Torr B; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Bacon A; Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom.
  • Knott C; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Jose S; Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom.
  • Vernon S; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Lüchtenborg M; Health Data Insight CIC, Cambridge, United Kingdom.
  • Pethick J; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Lavelle K; Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom.
  • McRonald F; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Eccles D; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Morris EJA; Health Data Insight CIC, Cambridge, United Kingdom.
  • Hardy S; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Turnbull C; Health Data Insight CIC, Cambridge, United Kingdom.
  • Tischkowitz M; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Pharoah P; National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Antoniou AC; Centre for Cancer, Society and Public Health, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Lancet Reg Health Eur ; 40: 100903, 2024 May.
Article em En | MEDLINE | ID: mdl-38745989
ABSTRACT

Background:

Second primary cancers (SPCs) after breast cancer (BC) present an increasing public health burden, with little existing research on socio-demographic, tumour, and treatment effects. We addressed this in the largest BC survivor cohort to date, using a novel linkage of National Disease Registration Service datasets.

Methods:

The cohort included 581,403 female and 3562 male BC survivors diagnosed between 1995 and 2019. We estimated standardized incidence ratios (SIRs) for combined and site-specific SPCs using incidences for England, overall and by age at BC and socioeconomic status. We estimated incidences and Kaplan-Meier cumulative risks stratified by age at BC, and assessed risk variation by socio-demographic, tumour, and treatment characteristics using Cox regression.

Findings:

Both genders were at elevated contralateral breast (SIR 2.02 (95% CI 1.99-2.06) females; 55.4 (35.5-82.4) males) and non-breast (1.10 (1.09-1.11) females, 1.10 (1.00-1.20) males) SPC risks. Non-breast SPC risks were higher for females younger at BC diagnosis (SIR 1.34 (1.31-1.38) <50 y, 1.07 (1.06-1.09) ≥50 y) and more socioeconomically deprived (SIR 1.00 (0.98-1.02) least deprived quintile, 1.34 (1.30-1.37) most).

Interpretation:

Enhanced SPC surveillance may benefit BC survivors, although specific recommendations require more detailed multifactorial risk and cost-benefit analyses. The associations between deprivation and SPC risks could provide clinical management insights.

Funding:

CRUK Catalyst Award CanGene-CanVar (C61296/A27223). Cancer Research UK grant PPRPGM-Nov 20∖100,002. This work was supported by core funding from the NIHR Cambridge Biomedical Research Centre (NIHR203312)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Lancet Reg Health Eur Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Lancet Reg Health Eur Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido